COMMENTARY: Novel Means to Selectively Identify Sertoli Cell Transplants
Abstract:Cell transplantation is inherently appealing as a potential treatment for a wide range of diseases characterized by the selective loss of cellular populations (6,10,12,17,21). Despite significant advances in transplantation biology over the past 20 years, the field continues to face numerous problems highlighted by limited human tissue sources and the need for chronic immunosuppression to prevent immune-mediated destruction of grafted tissue derived from both human and nonhuman sources. One potential strategy to overcome these obstacles creates an immunoprivileged site capable of maintaining the long-term viability of grafted tissue by harnessing the natural immunoregulatory capacity of Sertoli cells. Sertoli cells are normal constituents of the testes where they create a trophic-rich nurturing and immunoprotective environment (believed to be derived, in part, from the extensive production of cytokines and growth factors), capable of supporting nontesticular grafts (2,19,22). Indeed, the supportive and immunoprivileged nature of the intratesticular environment has been well documented for over 60 years (5). Since that time, several studies have confirmed that isolated Sertoli cells can provide trophic support for nontesticular transplantable cells (3,6,8,15) and can protect allogeneic and even xenogeneic tissue transplants in models of Parkinson’s disease (1,11,13–16,23) and diabetes (8,9,18–20,22,24).
Document Type: Miscellaneous
Affiliations: 1: *Sertoli Technologies, Inc., 766 Laten Knight Road, Cranston, RI 02921 2: †Center for Aging and Brain Repair, University of South Florida College of Medicine, 12901 Bruce B. Downs Blvd. MDC-78, Tampa, FL 33612
Publication date: June 1, 2002
- Cell Transplantation publishes original, peer-reviewed research and review articles on the subject of cell transplantation and its application to human diseases. To ensure high-quality contributions from all areas of transplantation, separate section editors and editorial boards have been established. Articles deal with a wide range of topics including physiological, medical, preclinical, tissue engineering, and device-oriented aspects of transplantation of nervous system, endocrine, growth factor-secreting, bone marrow, epithelial, endothelial, and genetically engineered cells, among others. Basic clinical studies and immunological research papers are also featured. To provide complete coverage of this revolutionary field, Cell Transplantation will report on relevant technological advances, and ethical and regulatory considerations of cell transplants. Cell Transplantation is now an Open Access journal starting with volume 18 in 2009, and therefore there will be an inexpensive publication charge, which is dependent on the number of pages, in addition to the charge for color figures. This will allow work to be disseminated to a wider audience and also entitle the corresponding author to a free PDF, as well as prepublication of an unedited version of the manuscript.